相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。P529. Longitudinal Illness- and Medication-Related Brain Volume Changes in Psychosis are Shaped by Connectome Architecture
Sidhant Chopra et al.
BIOLOGICAL PSYCHIATRY (2022)
Therapeutic use of melatonin in schizophrenia: A systematic review
Cathy Duan et al.
WORLD JOURNAL OF PSYCHIATRY (2021)
Modulating the Neuromodulators: Dopamine, Serotonin, and the Endocannabinoid System
Kate Z. Peters et al.
TRENDS IN NEUROSCIENCES (2021)
Prevention of schizophrenia deficits via non-invasive adolescent frontal cortex stimulation in rats
Ravit Hadar et al.
MOLECULAR PSYCHIATRY (2020)
Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study
Nakao Iwata et al.
SCHIZOPHRENIA RESEARCH (2020)
Hispidulin attenuates the social withdrawal in isolated disrupted-in-schizophrenia-1 mutant and chronic phencyclidine-treated mice
Akihiro Mouri et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
Naielly Rodrigues da Silva et al.
PHARMACOLOGICAL RESEARCH (2020)
Potential beneficial effects of caffeine administration in the neonatal period of an animal model of schizophrenia
Aline Camargo Ramos et al.
BEHAVIOURAL BRAIN RESEARCH (2020)
The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia
George A. Keepers et al.
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Deep hypothermia reverses behavioral and histological alterations in a rat model of perinatal asphyxia
Pablo Vazquez-Borsetti et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2019)
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia
Tibor Stark et al.
NEUROPHARMACOLOGY (2019)
Young spontaneously hypertensive rats (SHRs) display prodromal schizophrenia-like behavioral abnormalities
Suzy Tamie Niigaki et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2019)
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice
Kohei Takahashi et al.
NEUROPHARMACOLOGY (2019)
Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats
Marta Hereta et al.
PHARMACOLOGICAL REPORTS (2019)
Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders
Ashleigh L. Osborne et al.
BRAIN BEHAVIOR AND IMMUNITY (2019)
Reversal of MK-801-Induced Disruptions in Social Interactions and Working Memory with Simultaneous Administration of LY487379 and VU152100 in Mice
Paulina Cieslik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action
Nina Dedic et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Anti-inflammatory treatment with β-asarone improves impairments in social interaction and cognition in MK-801 treated mice
Xi Xiao et al.
BRAIN RESEARCH BULLETIN (2019)
Blonanserin ameliorates social deficit through dopamine-D3 receptor antagonism in mice administered phencyclidine as an animal model of schizophrenia
Saori Takeuchi et al.
NEUROCHEMISTRY INTERNATIONAL (2019)
Animal models of major depression: drawbacks and challenges
Barbara Planchez et al.
JOURNAL OF NEURAL TRANSMISSION (2019)
A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated with Schizophrenia
Takeshi Enomoto et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Ecological validity of social interaction tests in rats and mice
Kacper Kondrakiewicz et al.
GENES BRAIN AND BEHAVIOR (2019)
Animal models of PTSD: a challenge to be met
Gal Richter-Levin et al.
MOLECULAR PSYCHIATRY (2019)
Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm
Giancarlo Cerveri et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2019)
Approaches to neuromodulation for schizophrenia
Judith M. Gault et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Sodium nitroprusside is effective in preventing and/or reversing the development of schizophrenia-related behaviors in an animal model: The SHR strain
Mariana C. Diana et al.
CNS NEUROSCIENCE & THERAPEUTICS (2018)
Impaired social behaviors and minimized oxytocin signaling of the adult mice deficient in the N-methyl-D-aspartate receptor GluN3A subunit
Jin Hwan Lee et al.
EXPERIMENTAL NEUROLOGY (2018)
Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in N-Methyl-D-Aspartate Receptor Antagonist-Induced Rat Models of Schizophrenia
Masato Nakashima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
A schizophrenia-like behavioral trait in the SHR model: Applying confirmatory factor analysis as a new statistical tool
Fernanda Fiel Peres et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2018)
Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016
Fiona J. Charlson et al.
SCHIZOPHRENIA BULLETIN (2018)
The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia
Afzal Javed et al.
Frontiers in Psychiatry (2018)
Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia
Fernanda F. Peres et al.
FRONTIERS IN PHARMACOLOGY (2018)
Stem cell-derived interneuron transplants as a treatment for schizophrenia: preclinical validation in a rodent model
J. J. Donegan et al.
MOLECULAR PSYCHIATRY (2017)
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
Albert C. Yang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours
O. J. Onaolapo et al.
METABOLIC BRAIN DISEASE (2017)
Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model
Ashleigh L. Osborne et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Arginine vasopressin improves the memory deficits in Han Chinese patients with first-episode schizophrenia
Cai-Hong Geng et al.
PEPTIDES (2017)
Effects of intranasal oxytocin on symptoms of schizophrenia: A multivariate Bayesian meta-analysis
Donald R. Williams et al.
PSYCHONEUROENDOCRINOLOGY (2017)
Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy
Olakunle James Onaolapo et al.
PSYCHOPHARMACOLOGY (2017)
Intranasal Oxytocin May Improve High-Level Social Cognition in Schizophrenia, But Not Social Cognition or Neurocognition in General: A Multilevel Bayesian Meta-analysis
Paul-Christian Burkner et al.
SCHIZOPHRENIA BULLETIN (2017)
Endocannabinoid Signaling in the Control of Social Behavior
Don Wei et al.
TRENDS IN NEUROSCIENCES (2017)
Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research
Rafael N. Ruggiero et al.
FRONTIERS IN PHARMACOLOGY (2017)
Melatonin attenuates behavioural deficits and reduces brain oxidative stress in a rodent model of schizophrenia
Adejoke Y. Onaolapo et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Two-hit model of schizophrenia induced by neonatal immune activation and peripubertal stress in rats: Study of sex differences and brain oxidative alterations
Aline Santos Monte et al.
BEHAVIOURAL BRAIN RESEARCH (2017)
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model
A. Ghoshal et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Oxytocin reversed MK-801-induced social interaction and aggression deficits in zebrafish
Fernanda Francine Zimmermann et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
Jeffrey A. Lieberman et al.
BIOLOGICAL PSYCHIATRY (2016)
Therapeutic Potential of Cannabinoids in Psychosis
F. Markus Leweke et al.
BIOLOGICAL PSYCHIATRY (2016)
Potential of Oxytocin in the Treatment of Schizophrenia
Paul D. Shilling et al.
CNS DRUGS (2016)
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Peng Li et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Impact of Cognitive and Social Cognitive Impairment on Functional Outcomes in Patients With Schizophrenia
Michael F. Green
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Sub-chronic Antipsychotic Drug Administration Reverses the Expression of Neuregulin 1 and ErbB4 in a Cultured MK801-Induced Mouse Primary Hippocampal Neuron or a Neurodevelopmental Schizophrenia Model
Cunyan Li et al.
NEUROCHEMICAL RESEARCH (2016)
Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives
Maria Scherma et al.
PSYCHOPHARMACOLOGY (2016)
MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol
Serena Deiana et al.
BEHAVIOURAL PHARMACOLOGY (2015)
Pharmacological treatment of negative symptoms in schizophrenia
Hans-Jurgen Moeller et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2015)
Mice Lacking the Serotonin Htr2B Receptor Gene Present an Antipsychotic-Sensitive Schizophrenic-Like Phenotype
Pothitos M. Pitychoutis et al.
NEUROPSYCHOPHARMACOLOGY (2015)
The effect of combined treatment with risperidone and antidepressants on the MK-801-induced deficits in the social interaction test in rats
Katarzyna Kaminska et al.
Pharmacological Reports (2015)
Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia
Shigeyuki Chaki et al.
PSYCHOPHARMACOLOGY (2015)
Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
Felipe V. Gomes et al.
SCHIZOPHRENIA RESEARCH (2015)
A role for oxytocin in the etiology and treatment of schizophrenia
Megan Elizabeth Rich et al.
FRONTIERS IN ENDOCRINOLOGY (2015)
Relationships among Parvalbumin-Immunoreactive Neuron Density, Phase-Locked Gamma Oscillations, and Autistic/Schizophrenic Symptoms in PDGFR-β Knock-Out and Control Mice
Tomoya Nakamura et al.
PLOS ONE (2015)
Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression
E. Velthorst et al.
PSYCHOLOGICAL MEDICINE (2015)
Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials
Paolo Fusar-Poli et al.
SCHIZOPHRENIA BULLETIN (2015)
Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial
Mehran Mortazavi et al.
IRANIAN JOURNAL OF PSYCHIATRY AND BEHAVIORAL SCIENCES (2015)
Drug models of schizophrenia
Hannah Steeds et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2015)
PCP-induced deficits in murine nest building activity: Employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia
Christian Spang Pedersen et al.
BEHAVIOURAL BRAIN RESEARCH (2014)
Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia
Christina A. Wilson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: A randomized, double-blind, placebo-controlled, clinical trial
Seyed Mohammad Reza Hosseini et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor
Yuki Aoyama et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Determinants of Antipsychotic Response in Schizophrenia: Implications for Practice and Future Clinical Trials
Jonathan Rabinowitz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2014)
Rapid Tranquilization of Severely Agitated Patients With Schizophrenia Spectrum Disorders
Sebastian Walther et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Dopamine D2/D3 receptor binding of [123I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging
Y. R. Huang et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
Chronic Treatment with Mood-Stabilizers Attenuates Abnormal Hyperlocomotion of GluA1-Subunit Deficient Mice
Milica Maksimovic et al.
PLOS ONE (2014)
Minocycline alleviates behavioral deficits and inhibits microglial activation in the offspring of pregnant mice after administration of polyriboinosinic-polyribocytidilic acid
Furong Zhu et al.
PSYCHIATRY RESEARCH (2014)
Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: The SHR strain
Valeria Almeida et al.
SCHIZOPHRENIA RESEARCH (2014)
Emotion Deficits in People with Schizophrenia
Ann M. Kring et al.
ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 9 (2013)
Animal models of social avoidance and social fear
Iulia Toth et al.
CELL AND TISSUE RESEARCH (2013)
Role of Melatonin in Schizophrenia
Armando L. Morera-Fumero et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Systematic meta-analysis of childhood social withdrawal in schizophrenia, and comparison with data from at-risk children aged 9-14 years
Sandra L. Matheson et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2013)
Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules
Akihiro Mouri et al.
NEUROBIOLOGY OF DISEASE (2013)
Towards improved animal models for evaluating social cognition and its disruption in schizophrenia: The CNTRICS initiative
Mark J. Millan et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2013)
Animal models for predicting the efficacy and side effects of antipsychotic drugs
Pedro H. Gobira et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2013)
Psychosocial treatments for negative symptoms in schizophrenia: Current practices and future directions
Ori Elis et al.
CLINICAL PSYCHOLOGY REVIEW (2013)
The effects of antipsychotics on behavioral abnormalities of the Gunn rat (unconjugated hyperbilirubinemia rat), a rat model of schizophrenia
Keiko Tsuchie et al.
ASIAN JOURNAL OF PSYCHIATRY (2013)
Oxytocin in schizophrenia: a review of evidence for its therapeutic effects
Kai MacDonald et al.
ACTA NEUROPSYCHIATRICA (2012)
The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment
Oliver D. Howes et al.
ARCHIVES OF GENERAL PSYCHIATRY (2012)
Anandamide Dysfunction in Prodromal and Established Psychosis
F. Markus Leweke
CURRENT PHARMACEUTICAL DESIGN (2012)
Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model
Kristian Liaury et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophrenia
Ruben Antonio Vazquez-Roque et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2012)
To poly(I:C) or not to poly(I:C): Advancing preclinical schizophrenia research through the use of prenatal immune activation models
Urs Meyer et al.
NEUROPHARMACOLOGY (2012)
Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments
Martin Sarter et al.
NEUROPHARMACOLOGY (2012)
Pharmacological Activation of Group-II Metabotropic Glutamate Receptors Corrects a Schizophrenia-Like Phenotype Induced by Prenatal Stress in Mice
Francesco Matrisciano et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Animal models for medications development targeting alcohol abuse using selectively bred rat lines: Neurobiological and pharmacological validity
Richard L. Bell et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2012)
Social Cognitive Training for Schizophrenia: A Meta-Analytic Investigation of Controlled Research
Matthew M. Kurtz et al.
SCHIZOPHRENIA BULLETIN (2012)
Risk Factors for Psychosis: Impaired Social and Role Functioning
Barbara A. Cornblatt et al.
SCHIZOPHRENIA BULLETIN (2012)
Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia
Daniel C. Javitt et al.
SCHIZOPHRENIA BULLETIN (2012)
Schizophrenia: Treatment Targets Beyond Monoamine Systems
Hisham M. Ibrahim et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats
Mariana Bendlin Calzavara et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Antipsychotic drugs reverse MK-801-induced cognitive and social interaction deficits in zebrafish (Danio rerio)
Kelly Juliana Seibt et al.
BEHAVIOURAL BRAIN RESEARCH (2011)
Animal models of schizophrenia
C. A. Jones et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
PDE10A Inhibitors: Novel Therapeutic Drugs for Schizophrenia
Jan Kehler et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine
F. Markus Leweke et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2011)
The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: A meta-analysis
Anne-Kathrin J. Fett et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2011)
Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia
Cort A. Pedersen et al.
SCHIZOPHRENIA RESEARCH (2011)
Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis
Surendra P. Singh et al.
BRITISH JOURNAL OF PSYCHIATRY (2010)
Measuring Social Functioning With the Personal and Social Performance Scale in Patients With Acute Symptoms of Schizophrenia: Interpretation of Results of a Pooled Analysis of Three Phase III Trials of Paliperidone Extended-Release Tablets
Donald L. Patrick et al.
CLINICAL THERAPEUTICS (2010)
Cannabinoid-Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
Javier Fernandez-Ruiz et al.
CNS NEUROSCIENCE & THERAPEUTICS (2010)
Pharmacologic Treatment of Behavioral Symptoms Associated With Autism and Other Pervasive Developmental Disorders
Logan K. Wink et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2010)
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats
Alexandre Seillier et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Animal models of neuropsychiatric disorders
Eric J. Nestler et al.
NATURE NEUROSCIENCE (2010)
Combination Therapy in the Treatment of Schizophrenia
C. Wolff-Menzler et al.
PHARMACOPSYCHIATRY (2010)
Epidemiology-driven neurodevelopmental animal models of schizophrenia
Urs Meyer et al.
PROGRESS IN NEUROBIOLOGY (2010)
Antipsychotic medication and social cue recognition in chronic schizophrenia
David Leland Roberts et al.
PSYCHIATRY RESEARCH (2010)
The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements
Lisa B. Dixon et al.
SCHIZOPHRENIA BULLETIN (2010)
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Robert W. Buchanan et al.
SCHIZOPHRENIA BULLETIN (2010)
Sex differences in schizophrenia
Kathryn M. Abel et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
The neonatal ventral hippocampal lesion as a heuristic neurodevelopmental model of schizophrenia
Kuei Y. Tseng et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Passive/Apathetic Social Withdrawal and Active Social Avoidance in Schizophrenia Difference in Underlying Psychological Processes
Charlotte Fredslund Hansen et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2009)
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia
Jared W. Young et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: A three-dimensional analysis with sLORETA
Tomiki Sumiyoshi et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2009)
Effects of Bisphenol-A and Other Endocrine Disruptors Compared With Abnormalities of Schizophrenia: An Endocrine-Disruption Theory of Schizophrenia
James S. Brown
SCHIZOPHRENIA BULLETIN (2009)
Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand
Yang Guo et al.
SCHIZOPHRENIA RESEARCH (2009)
Effect of risperidone on emotion recognition deficits in antipsychotic-naive schizophrenia: A short-term follow-up study
Rishikesh V. Behere et al.
SCHIZOPHRENIA RESEARCH (2009)
Social functioning deficits in young people at risk for schizophrenia
GeumSook Shim et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2008)
The Role of Phosphodiesterases in Schizophrenia
Judith A. Siuciak
CNS DRUGS (2008)
Social Cognition in Schizophrenia: An NIMH Workshop on Definitions, Assessment, and Research Opportunities
Michael F. Green et al.
SCHIZOPHRENIA BULLETIN (2008)
Social cognition in schizophrenia: An overview
David L. Penn et al.
SCHIZOPHRENIA BULLETIN (2008)
Mice lacking the immediate early gene Egr3 respond to the anti-aggressive effects of clozapine yet are relatively resistant to its sedating effects
Amelia Gallitano-Mendel et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Bidirectional cannabinoid modulation of social behavior in adolescent rats
Viviana Trezza et al.
PSYCHOPHARMACOLOGY (2008)
Progressive changes in the development toward schizophrenia:: Studies in subjects at increased symptomatic risk
Stephen J. Wood et al.
SCHIZOPHRENIA BULLETIN (2008)
Effect size, confidence interval and statistical significance: a practical guide for biologists
Shinichi Nakagawa et al.
BIOLOGICAL REVIEWS (2007)
Chinese herbal medicine for schizophrenia - Cochrane systematic review of randomised trials
John Rathbone et al.
BRITISH JOURNAL OF PSYCHIATRY (2007)
The effect of antipsychotic treatment on Theory of Mind
Romina Mizrahi et al.
PSYCHOLOGICAL MEDICINE (2007)
Synergistic effect of galantamine with risperidone on impairment of social interaction in phencyclidine-treated mice as a schizophrenic animal model
Dayong Wang et al.
NEUROPHARMACOLOGY (2007)
The functional significance of social cognition in schizophrenia: A review
Shannon M. Couture et al.
SCHIZOPHRENIA BULLETIN (2006)
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: Implications for the neuropathology of schizophrenia
Holly Moore et al.
BIOLOGICAL PSYCHIATRY (2006)
Effects of age and sex on olanzapine hasma concentrations
U Weiss et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials
C Rummel et al.
SCHIZOPHRENIA RESEARCH (2005)
Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin
PR Lee et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Effects of antipsychotic treatment on emotion perception deficits in first-episode schizophrenia
ES Herbener et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
(+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia
JP Rung et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2005)
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
S Miyamoto et al.
MOLECULAR PSYCHIATRY (2005)
Predicting schizophrenia: findings from the Edinburgh high-risk study
EC Johnstone et al.
BRITISH JOURNAL OF PSYCHIATRY (2005)
Do clozapine and risperidone affect Social Competence and problem solving?
AS Bellack et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia
LE Rueter et al.
PSYCHOPHARMACOLOGY (2004)
Schizophrenia and employment - A review
S Marwaha et al.
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY (2004)
Haloperidol and clozapine affect social behaviour in rats postnatally lesioned in the ventral hippocampus
A Becker et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2003)
Neurogenesis in cerebral heterotopia induced in rats by prenatal methylazoxymethanol treatment
G Battaglia et al.
CEREBRAL CORTEX (2003)
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations
O Freudenreich et al.
ACTA PSYCHIATRICA SCANDINAVICA (2002)
Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat
VA Russell
BEHAVIOURAL BRAIN RESEARCH (2002)
Neuropsychological correlates of hippocampal volumes in patients experiencing a first episode of schizophrenia
PR Szeszko et al.
AMERICAN JOURNAL OF PSYCHIATRY (2002)
Impact of normal sexual dimorphisms on sex differences in structural brain abnormalities in schizophrenia assessed by magnetic resonance Imaging
JM Goldstein et al.
ARCHIVES OF GENERAL PSYCHIATRY (2002)
Neonatal nitric oxide synthase inhibition: social interaction deficits in adulthood and reversal by antipsychotic drugs
MD Black et al.
NEUROPHARMACOLOGY (2002)
Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
M Lundblad et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2002)
Broad therapeutic uses of atypical antipsychotic medications
PF Buckley
BIOLOGICAL PSYCHIATRY (2001)
Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis
JAC Sterne et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2001)
Genetic animal models: focus on schizophrenia
RR Gainetdinov et al.
TRENDS IN NEUROSCIENCES (2001)
Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses
KI Melkersson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Antipsychotic drugs, dopamine receptors, and schizophrenia
P Seeman
CLINICAL NEUROSCIENCE RESEARCH (2001)
分享论文
